{"id":1063263,"date":"2011-07-31T15:56:48","date_gmt":"2011-07-31T15:56:48","guid":{"rendered":"http:\/\/www.longevitymedicine.tv\/international-stem-cell-corporation-to-hold-business-update-conference-call-on-august-10\/"},"modified":"2024-08-17T20:28:14","modified_gmt":"2024-08-18T00:28:14","slug":"international-stem-cell-corporation-to-hold-business-update-conference-call-on-august-10-2","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/stem-cell-therapy\/international-stem-cell-corporation-to-hold-business-update-conference-call-on-august-10-2.php","title":{"rendered":"International Stem Cell Corporation to Hold Business Update Conference Call on August 10"},"content":{"rendered":"
International Stem Cell Corporation (OTCBB: ISCO)<\/b> <\/span><\/b><\/span>today announced that it will hold a conference call and webcast on Wednesday, August 10, 2011 at 11:00 a.m. Eastern (8:00 a.m. Pacific). Chairman Ken Aldrich will provide an update on the business, including plans for the future development of the skin care line; animal and potential clinical trials for Parkinson's and liver diseases; and the Company's business strategy for 2011 and longer term.<\/span><\/div>
<\/div>
Individuals interested in listening to the conference call may do so by dialing <\/span><\/span>877-407-8033<\/span><\/a> <\/span><\/span>for domestic callers, or <\/span><\/span>201-689-8033<\/span><\/a> <\/span><\/span>for international callers, or from the webcast on the investor relations section of the Company's Web site athttp:\/\/www.intlstemcell.com<\/a><\/span><\/a>.<\/span><\/div>
<\/div>
A telephone replay will be available approximately one hour after the conclusion of the call by dialing <\/span><\/span>877-660-6853<\/span><\/a> <\/span><\/span>for domestic callers, or <\/span><\/span>201-612-7415<\/span><\/a> <\/span><\/span>for international callers, and entering the account code: 286 and the Conference ID: 376367. The webcast will be available on the Company's Web site for 60 days following the completion of the call.<\/span><\/div>
<\/div>
About International Stem Cell Corporation<\/span><\/b><\/div>
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at <\/span><\/span>http:\/\/www.internationalstemcell.com<\/a><\/span><\/a>.<\/span><\/div>

<\/span><\/div>
To subscribe to receive ongoing corporate communications, please click on the following link: <\/span><\/span>http:\/\/www.b2i.us\/irpass.asp?BzID=1468&to=ea&s=0<\/a><\/span><\/a>.<\/span><\/div>
<\/div>
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383<\/span><\/a>
kaldrich@intlstemcell.com<\/a><\/span><\/a>
or
Lippert\/Heilshorn & Associates
Don Markley, <\/span><\/span>310-691-7100<\/span><\/a>
dmarkley@lhai.com<\/a><\/span><\/a><\/span><\/div>
<\/div>
\"\"<\/div>","protected":false},"excerpt":{"rendered":"

International Stem Cell Corporation (OTCBB: ISCO) today announced that it will hold a conference call and webcast on Wednesday, August 10, 2011 at 11:00 a.m. Eastern (8:00 a.m. Pacific). Chairman Ken Aldrich will provide an update on the business, including plans … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[25,1246878],"tags":[],"class_list":["post-1063263","post","type-post","status-publish","format-standard","hentry","category-stem-cell-therapy","category-stem-cells"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1063263"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1063263"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1063263\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1063263"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1063263"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1063263"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}